MedEsthetics magazines offers business education and in-depth coverage of the latest noninvasive cosmetic procedures for physicians and practice managers working in the medical aesthetics industry.
Issue link: https://medesthetics.epubxp.com/i/535392
62 JULY/AUGUST 2015 | Med Esthetics NEWS & EVENTS American Academy of Dermatology (AAD). The International Society Annual Meeting Travel Grant: Recipients will travel to dermatology meetings in Asia, Europe and Latin America, where they will have the chance to meet and develop relationships with foreign colleagues. There are 29 grants available to dermatology residents, fellows and young dermatologists (those who have completed residency within the last fi ve years) from the U.S. and Canada. The Resident International Grant: Senior derma tology residents will receive funding to participate in a four- to six-week elective in Botswana, where they will help administer dermatologic HIV care and visit outreach sites. There are 15 grants available to U.S. and Canadian residents. The application deadline for both grants is Wednesday, September 30, 2015. For more information, visit aad.org. AACS REINSTITUTES FELLOWSHIP PROGRAMS The American Academy of Cosmetic Surgery (AACS) is re-establishing its Facial Fellowship Programs and General Cosmetic Surgery Fellowship Programs, which qualify fellow candidates to sit for the facial cosmetic surgery board exam. The AACS is accepting applications for both fellowship directors—to qualify, you must be a Diplomate of the American Board of Cosmetic Surgery (ABCS) as well as a current fellow-level member of the AACS—and fellowship trainees. For more information, visit cosmeticsurgery.org. ASDS ESTABLISHES FREDERIC S. BRANDT MEMORIAL FUNDS The American Society for Dermatologic Surgery (ASDS) has set up two memorial funds to honor the late Frederic S. Brandt, MD, an ASDS member for over 30 years who passed away earlier this year. The funds will provide opportunities for ASDS members, industry and interested donors to support the fi eld of cosmetic dermatology that Dr. Brandt held dear. The Allergan Foundation has committed $300,000 to The Frederic S. Brandt, MD, Innovations in Aesthetics Fellowship Fund—which will be administered in collaboration with the ASDS accredited Cosmetic Dermatologic Surgery Fellowship training programs—to support the career development of junior dermatologic surgeon-scientists focused on cosmetic treatments and patient care. The Allergan Foundation will fund and support two fellows per year. The ASDS has also established the Fredric S. Brandt, MD, Memorial Research Fund to support cosmetic dermatologic clinical research projects and board- directed research related to the safety of cosmetic procedures. For information on donating to either fund, email Tara Azzano at tazzano@asds. net or call 847.956.9128. NEOTHETICS INITIATES PHASE 3 TRIALS FOR ABDOMINAL FAT REDUCING INJECTABLE Specialty pharmaceutical company Neothetics will begin two Phase 3 trials— AbCONTOUR1 and AbCONTOUR2— of LIPO-202, the fi rst noninvasive drug candidate for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects. LIPO-202 is an injectable formulation of salmeterol xinafoate, a long-acting ß2-adrenergic receptor agonist that activates ß2- adrenergic receptors on fat cells, triggering the breakdown of triglycerides stored in the cells and causing lipolysis. Previous studies have indicated that LIPO-202 safely and effectively reduced central abdominal bulging. The randomized, double-blind, place bo- controlled studies will assess a total weekly dose of 0.40mcg of LIPO-202 injected over eight weeks. A total of 1,600 patients will be enrolled and randomized 1:1 to LIPO-202 or placebo. The trials will be conducted in approximately 80 sites across the U.S. "The initiation of our Phase 3 pivotal AbCONTOUR1 and AbCONTOUR2 trials advances late-stage development of our potentially best-in-class, non-surgical procedure for the reduction of central abdominal bulging. The achievement of this milestone moves Neothetics one step closer to fi lling a large unmet need for a safe, effective, non-invasive drug treatment for abdominal body contouring," said George Mahaffey, president and CEO of Neothetics. ELSEVIER TO PUBLISH JID The Society for Investigative Dermatology